Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 126 participants.
Also called NCT07255820
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 126 participants
- Sponsor
- Registry
-
NCT07255820
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Pakistan
- Registry status
- Completed
Technical summary
Registry record NCT07255820. Randomized; no masking; primary purpose treatment. Start 2026-01-01 (actual); primary completion 2026-03-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Mellitus Patients With Elevated LDL Cholesterol
- Condition
- Type 2 Diabetes Mellitus
- Condition
- Hypercholesterolemia / Elevated LDL Cholesterol
- Intervention (Drug)
- Rosuvastatin + Ezetimibe
- Intervention (Drug)
- Bempedoic Acid + Ezetimibe
- Intervention (Drug)
- Rosuvastatin + Ezetimibe + Bempedoic Acid
- Lead sponsor
- Bahria University
Record details
- Record id
cardio:ct-nct07255820- Content hash
97882f5701bcab64d9407c41f2d9a8cd898a0dfb77f2a3ff4d3ce7c73d165689